Skip to main content


Cellis Sp. z o.o. implements following projects:

Macrophage-based immunotherapy of platinum-resistant ovarian cancer

This project has received funding from the European Union’s Horizon 2022 research and innovation programme EIC Transition under grant agreement No. 101099232. Project started on November 1st, 2022.

Aim: The project aims to develop an innovative allogeneic, “ready-to-use” macrophage-based therapy for platinum-resistant ovarian cancer.

Planned effects: The project will generate of complete efficacy data package for the pre-clinical development of MDC-735 product, consisting of efficacy in multiple animal models for platinum-resistant ovarian cancer, PK, PD and toxicology study as well as consolidate IP and validate business case. The result of the project will be a validated cell therapy product for platinum-refractory ovarian cancer, tested for effectiveness and ready-to-use for the Phase I clinical trial.

EU funding: EUR 2,499,998.75

Project value: EUR 2,499,998.75


Innovative cell-based glioma therapy

This project is co-financed by European Union Funds.

Aim: The aim of the project is to develop an innovative “first in class” cell therapy for glioma using macrophages loaded with a complex of protein-drug will (with cooperation with UHZ in Zurich). At the end of the project the product will be ready to enter clinical trials.

Planned effects: The main result of the project (product innovation) will be a validated glioma therapy, ready to be tested in “First in Man” clinical trial and further development by large pharmaceutical companies.

EU funding: PLN 17,359,036.24

Project value: PLN 21,890,639.07